Michael Gelband’s IGC Pharma IGC Stock Holding History

Michael Gelband’s Portfolio IGC Stock Details IGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-13,049	Closed	-$7K	–	2079
2022 Q2	$7K	Buy	+13,049	New	+$8.23K	﹤0.01%	1869

Other funds holding IGC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dearborn Partners Chicago, Illinois $1.77B AUM 9.47% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

VIA

Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Michael Gelband's IGC Position: Q3 2022 in Review

Michael Gelband sold out of IGC Pharma (IGC) in Q3 2022, closing a stake of 13,049 shares — an estimated $7K sold.

Michael Gelband first reported a position in IGC in Q2 2022 and held it in 1 quarter. The position peaked at $7K in Q2 2022. 26 funds tracked by Wall St. Rank hold IGC as of Q3 2022.

Michael Gelband reported no remaining IGC Pharma position as of Q3 2022 after selling out during the quarter.
Michael Gelband sold 13,049 IGC Pharma shares in Q3 2022, an estimated $7K.
Michael Gelband first reported a position in IGC Pharma in Q2 2022 and held it in 1 quarter.
Michael Gelband's IGC Pharma position peaked at $7K in Q2 2022.
26 funds tracked by Wall St. Rank held IGC Pharma as of Q3 2022.

Based on ExodusPoint Capital Management's 13F filing for Q3 2022, filed 10 Nov 2022.